you are here: Home News Novo Nordisk

Novo Nordisk

How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India
Roche to buy 89bio for up to $3.5 billion in obesity push
How Novo Nordisk lost its lead in the weight loss race
Novo Nordisk launches blockbuster weight loss drug Wegovy in India
Activist hedge fund Parvus builds stake in Novo Nordisk as leadership search begins
Novo preparing for early launch of weight-loss drug Wegovy in India
Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential
Divis Lab: GLP-1 opportunity to unfold in the medium term
Novo Nordisk falls most on record after new weight drug disappoints
Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms: Report
Biocon’s formulations business to outpace API share soon: CEO
Dr Reddy’s: Watchful of the Revlimid cliff
Riding on Novo Nordisk’s semaglutide, India’s weight-loss market triples in size in 2 years
Novo Nordisk's parent invests in India's Manipal hospital chain
Popular weight-loss drugs like Wegovy may raise risk of complications under anaesthesia
All you need to know about Mounjaro, the antidiabetic injectable also touted as the most powerful weight-loss drug ever
Efforts on to launch once-a week- insulin in India by mid-2025: Novo Nordisk MD
Fat-busting diabetes drug is a global smash hit but remains prohibitively pricey for many Indians
Novo Nordisk, Roche partner to enhance Type 1 Diabetes care for children in India
Smart insulin is the future: Vikrant Shrotriya of Novo Nordisk
Novo Nordisk joins hands with AMR Action Fund to fight antimicrobial resistance
Novo Nordisk names Vikrant Shrotriya as new India head
Novo Nordisk remains on the hunt for biopharma deals
Drugmaker Novo Nordisk bets $145 mn on post-Brexit UK science
Novo Nordisk says to cut 1,000 jobs

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Novo Nordisk

How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India

Roche to buy 89bio for up to $3.5 billion in obesity push

How Novo Nordisk lost its lead in the weight loss race

Novo Nordisk launches blockbuster weight loss drug Wegovy in India

Activist hedge fund Parvus builds stake in Novo Nordisk as leadership search begins

Novo preparing for early launch of weight-loss drug Wegovy in India

Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential

Divis Lab: GLP-1 opportunity to unfold in the medium term

Novo Nordisk falls most on record after new weight drug disappoints

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms: Report

Biocon’s formulations business to outpace API share soon: CEO

Dr Reddy’s: Watchful of the Revlimid cliff

Riding on Novo Nordisk’s semaglutide, India’s weight-loss market triples in size in 2 years

Novo Nordisk's parent invests in India's Manipal hospital chain

Popular weight-loss drugs like Wegovy may raise risk of complications under anaesthesia

All you need to know about Mounjaro, the antidiabetic injectable also touted as the most powerful weight-loss drug ever

Efforts on to launch once-a week- insulin in India by mid-2025: Novo Nordisk MD

Fat-busting diabetes drug is a global smash hit but remains prohibitively pricey for many Indians

Novo Nordisk, Roche partner to enhance Type 1 Diabetes care for children in India

Smart insulin is the future: Vikrant Shrotriya of Novo Nordisk

Novo Nordisk joins hands with AMR Action Fund to fight antimicrobial resistance

Novo Nordisk names Vikrant Shrotriya as new India head

Novo Nordisk remains on the hunt for biopharma deals

Drugmaker Novo Nordisk bets $145 mn on post-Brexit UK science

Novo Nordisk says to cut 1,000 jobs